Strongbridge Biopharma plc Announces Top-Line Results from Extended Evaluation Phase of the Pivotal Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Potential Treatment of Endogenous Cushing’s Syndrome March 11, 2019 - NASDAQ Companies 0 » View More News for March 11, 2019
